2024³â ´ëÇѹé½ÅÇÐȸ Á¦23Â÷ Ãá°èÇмú´ëȸ : 2024-03-29
±³À°ÀÏÀÚ : 2024-03-29
±³À°Àå¼Ò : °¡Å縯´ëÇб³ ¿È´Ï¹ö½ºÆÄÅ© ÄÁº¥¼ÇȦ
±³À°ÁÖÁ¦ : 2024³â ´ëÇѹé½ÅÇÐȸ Á¦23Â÷ Ãá°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѹé½ÅÇÐȸ
´ã´çÀÚ : ±è¿¬¾Æ
¿¬¶ôó : 02-597-2353
À̸ÞÀÏ : office@korvac.org
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, °áÇÙ°ú, ¹Ì»ý¹°ÇÐ
Âü¼®¿¹»óÀÎ : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í "Àü¹®ÀÇ, ¹Ú»ç±Þ ÀÌ»ó ¼±ÀÓ ¹× Ã¥ÀÓ¿¬±¸ÀÚ: 5¸¸¿ø
Àü°øÀÇ, ´ëÇлý, ´ëÇпø»ý ¹× ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø: 3¸¸¿ø"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03¿ù 29ÀÏ ¿È´Ï¹ö½ºÆÄÅ© ÄÁº¥¼ÇȦ 09:00~09:30 Germinal center-driven maturation of B cell response to SARS-CoV-2 mRNA vaccination ±è¿ì¼·(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03¿ù 29ÀÏ ¿È´Ï¹ö½ºÆÄÅ© ÄÁº¥¼ÇȦ 09:30~10:00 Induction of T-bet+ atypical memory B cells by COVID-19 mRNA vaccines ¹Ú¼öÇü(KAIST)
±³À°½Ã°£ 03¿ù 29ÀÏ ¿È´Ï¹ö½ºÆÄÅ© ÄÁº¥¼ÇȦ 10:00~10:30 Memory T cell responses elicited by SARS-CoV-2 vaccination and breakthrough infection Á¤¹Î°æ(IBS)
ÈÞ½Ä 03¿ù 29ÀÏ ¿È´Ï¹ö½ºÆÄÅ© ÄÁº¥¼ÇȦ 10:30~10:40 Coffee break ( )
±³À°½Ã°£ 03¿ù 29ÀÏ ¿È´Ï¹ö½ºÆÄÅ© ÄÁº¥¼ÇȦ 10:40~11:10 Universal influenza vaccine Á¤´ë±Õ(Çѱ¹»ý¸í°øÇבּ¸¿ø)
±³À°½Ã°£ 03¿ù 29ÀÏ ¿È´Ï¹ö½ºÆÄÅ© ÄÁº¥¼ÇȦ 11:10~11:40 Development of tuberculosis vaccine ½Å¼ºÀç(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 03¿ù 29ÀÏ ¿È´Ï¹ö½ºÆÄÅ© ÄÁº¥¼ÇȦ 11:40~12:10 African swine fever vaccine review ÃÖÁر¸(³ó¸²Ãà»ê°Ë¿ªº»ºÎ)
±âŸ 03¿ù 29ÀÏ ¿È´Ï¹ö½ºÆÄÅ© ÄÁº¥¼ÇȦ 12:10~13:10 Satellite symposium ( )
±³À°½Ã°£ 03¿ù 29ÀÏ ¿È´Ï¹ö½ºÆÄÅ© ÄÁº¥¼ÇȦ 13:10~13:40 Epidemiology and control strategies of measles ÇãÁß¿¬(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 03¿ù 29ÀÏ ¿È´Ï¹ö½ºÆÄÅ© ÄÁº¥¼ÇȦ 13:40~14:10 Pertussis: disease burden and vaccination policy ÀÌÈ¿Áø(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03¿ù 29ÀÏ ¿È´Ï¹ö½ºÆÄÅ© ÄÁº¥¼ÇȦ 14:10~14:40 Mosquito-borne diseases vaccine development: Zika & Chikungunya ÀÓÀçÇü(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 03¿ù 29ÀÏ ¿È´Ï¹ö½ºÆÄÅ© ÄÁº¥¼ÇȦ 14:40~15:10 RSV vaccination in the elderly and pregnant woman ±è¼ºÇÑ(¿ï»êÀÇ´ë)
ÈÞ½Ä 03¿ù 29ÀÏ ¿È´Ï¹ö½ºÆÄÅ© ÄÁº¥¼ÇȦ 15:10~15:20 Coffee break ( )
±³À°½Ã°£ 03¿ù 29ÀÏ ¿È´Ï¹ö½ºÆÄÅ© ÄÁº¥¼ÇȦ 15:20~15:50 VZV vaccine: need for the 2nd dose °Çö¹Ì(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03¿ù 29ÀÏ ¿È´Ï¹ö½ºÆÄÅ© ÄÁº¥¼ÇȦ 15:50~16:20 Pneumococcal vaccination: update and perspectives À±±â¿í(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03¿ù 29ÀÏ ¿È´Ï¹ö½ºÆÄÅ© ÄÁº¥¼ÇȦ 16:20~16:50 HPV vaccine: expanded valency and gender neutral vaccination ÀÌÇöÁÖ(¼¿ïÀÇ´ë)